南宫NG·28(中国)相信品牌力量

Changchun, China – On July 22, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the First Three Northeast Provinces Aortic Disease Interventional Treatment Summit held in Changchun. Hosted by Chinese Association of Cardiovascular Surgeons and the First Hospital of Jilin University, the summit provided a platform for clinicians to exchange ideas on hot topics and difficult cases of aortic disease interventional treatment through typical case studies and special lectures.

During the summit, several experts shared their personal experience in using MicroPort® Endovascular's aortic products. Professor Wei Bi of the Second Hospital of Hebei Medical University delivered a speech of "the Application of Unibody Stent in Treating Abdominal Aortic Pseudoaneurysm." He pointed out, there is a risk of type III endoleak and long-term migration of the modular stent–graft, of which the incidence of later migration is as high as 3% to 28%. To answer such limitation, Aegis® Bifurcated Stent-Graft System ("Aegis®"), in-house developed by MicroPort® Endovascular, is designed to be anchored on the aortic bifurcation based on the "anatomical fixation" concept to avoid the risk of stent graft's migration to the distal as well as the risk of Type III endoleak between main body and extension leg. The product is specially indicated for the treatment of abdominal aortic pseudoaneurysm, Iliac aneurysm, abdominal aortic dissection, and abdominal aortic disease with localized stenosis or plenty of mural thrombus, and is the primary solution for some special cases.

Professor Weiliang Jiang of the Second Affiliated Hospital of Harbin Medical University lectured on "Different Methods of the Revascularization of the Supra-Arch Branches and Outcome Evaluation," in which he compared fenestrated technique, chimney technique, hybrid technique, and branch stent. He said, MicroPort® Endovascular's Castor® Branched Aortic Stent-Graft System ("Castor®") is the world's first aortic stent formally applied to clinical practice to fulfill the branches reconstruction of aortic arch. Compared to fenestrated technique, chimney technique, and supra-arch branch bypass, its unibody design is consistent with the anatomy of the arch which helps to avoid endoleak and neurological complications.

Professor Xiaoming Zhang of Peking University People's Hospital shared "Treatment Strategies of Aortic Arch," in which he analyzed the pros and cons of traditional treatment, interventional treatment, and hybrid procedure. Professor Xiaoming Zhang respectively introduced Castor® and CRONUS® Surgical Stent Graft System ("CRONUS®") of MicroPort® Endovascular. When treating lesions involving ascending aorta and aortic arch, CRONUS® successfully combines traditional open surgery and advanced interventional approaches, and significantly reduces the prevalence of morbidity and mortality and increases the success rate by endovascular treatment of the descending aortic disease. Castor® is the first endovascular device used to preserve the branch artery while repair the thoracic aorta. Its unique "unibody design" could accommodate diverse arch anatomy. It is also the world's first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery and 20mm distal to the left carotid artery.

Meanwhile, MicroPort® Endovascular introduced to the attendees the development history and future trend of its product portfolio, as well as the design, features and advantages of its existing products. MicroPort® Endovascular primarily focuses on R&D, and manufacturing support of the interventional medical devices, including AAA/TAA stent graft systems, surgical stent graft system, aortic balloon dilation catheter and peripheral vascular stents/balloons. It will continue to strive for innovation and product diversification, to help promote the development of China's aortic surgical technique.